CytRx and SynthRx, Galapagos Genomics, Alnylam Pharmaceuticals, Nucleonics and University of California, and Sirna Therapeutics | GenomeWeb

CytRx Closes SynthRx Deal

CytRx said this week that it has closed its deal to exclusively license its phase III sickle cell disease drug Flocor, as well as its OptiVax vaccine delivery technology, to SynthRx, a Houston-based startup firm founded and run by Robert Hunter, a CytRx co-founder and chairman of the University of Texas' department of pathology and laboratory medicine.

The assets were leftovers from the time before CytRx acquired Global Genomics and was repositioned as an RNAi therapeutics firm.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.